Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina

La leishmaniasis es una enfermedad zoonótica causada por el protozoario Leishmania spp, el cual presenta dos estadios en su ciclo de vida (amastigote y promastigote) siendo los amastigotes intracelulares obligados. Este patógeno ataca principalmente células del sistema inmunitario por lo que desenca...

Full description

Autores:
Caro Linares, Daniel Andrés
Rocha Rodriguez, Luisa Fernanda
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2023
Institución:
Universidad Cooperativa de Colombia
Repositorio:
Repositorio UCC
Idioma:
OAI Identifier:
oai:repository.ucc.edu.co:20.500.12494/53800
Acceso en línea:
https://hdl.handle.net/20.500.12494/53800
Palabra clave:
Lutzomya longipalpis
Sistema inmunológico
Caninos
Macrófagos
Linfocitos
Th1
TG 2023 MVZ 53800
Lutzomya longipalpis
Immune system
Canines
Macrophages
Lymphocytes
Th1
Rights
openAccess
License
Atribución – No comercial – Compartir igual
id COOPER2_e77614a6807601e98480a17da6c659a9
oai_identifier_str oai:repository.ucc.edu.co:20.500.12494/53800
network_acronym_str COOPER2
network_name_str Repositorio UCC
repository_id_str
dc.title.none.fl_str_mv Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
title Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
spellingShingle Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
Lutzomya longipalpis
Sistema inmunológico
Caninos
Macrófagos
Linfocitos
Th1
TG 2023 MVZ 53800
Lutzomya longipalpis
Immune system
Canines
Macrophages
Lymphocytes
Th1
title_short Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
title_full Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
title_fullStr Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
title_full_unstemmed Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
title_sort Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina
dc.creator.fl_str_mv Caro Linares, Daniel Andrés
Rocha Rodriguez, Luisa Fernanda
dc.contributor.advisor.none.fl_str_mv Plazas Hernández, Fernely Augusto
Pérez Rubio, María del Rocío
dc.contributor.author.none.fl_str_mv Caro Linares, Daniel Andrés
Rocha Rodriguez, Luisa Fernanda
dc.subject.none.fl_str_mv Lutzomya longipalpis
Sistema inmunológico
Caninos
Macrófagos
Linfocitos
Th1
topic Lutzomya longipalpis
Sistema inmunológico
Caninos
Macrófagos
Linfocitos
Th1
TG 2023 MVZ 53800
Lutzomya longipalpis
Immune system
Canines
Macrophages
Lymphocytes
Th1
dc.subject.classification.none.fl_str_mv TG 2023 MVZ 53800
dc.subject.other.none.fl_str_mv Lutzomya longipalpis
Immune system
Canines
Macrophages
Lymphocytes
Th1
description La leishmaniasis es una enfermedad zoonótica causada por el protozoario Leishmania spp, el cual presenta dos estadios en su ciclo de vida (amastigote y promastigote) siendo los amastigotes intracelulares obligados. Este patógeno ataca principalmente células del sistema inmunitario por lo que desencadena diversos procesos tales como los de tipo inflamatorio. Actualmente en caninos se usan diferentes fármacos para su tratamiento pero estos son desgastantes ya que presentan efectos adversos, son costosos y su uso prolongado ha causado resistencia, lo que potencia las lesiones causadas por el parásito, por esta razón se exponen alternativas como coadyuvantes para el tratamiento y control de la enfermedad que actúan sobre el sistema inmunológico de manera directa o indirecta, como por ejemplo la domperidona, los nucleótidos y compuesto correlacionado de hexosa activa (AHCC), extractos de plantas, receptores tipo toll (TLR) y citocinas, además se mencionan las vacunas disponibles comercialmente para su uso como método preventivo.
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2023-12-13T15:52:55Z
dc.date.available.none.fl_str_mv 2023-12-13T15:52:55Z
dc.date.issued.none.fl_str_mv 2023-12-13
dc.type.none.fl_str_mv Trabajo de grado - Pregrado
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.version.none.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_7a1f
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12494/53800
dc.identifier.bibliographicCitation.none.fl_str_mv Caro Linares, D. A. y Rocha Rodriguez, L. F. (2023). Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina. [Tesis de pregrado, Universidad Cooperativa de Colombia]. Repositorio Institucional UCC. https://repository.ucc.edu.co/handle/20.500.12494/53800
url https://hdl.handle.net/20.500.12494/53800
identifier_str_mv Caro Linares, D. A. y Rocha Rodriguez, L. F. (2023). Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina. [Tesis de pregrado, Universidad Cooperativa de Colombia]. Repositorio Institucional UCC. https://repository.ucc.edu.co/handle/20.500.12494/53800
dc.relation.references.none.fl_str_mv Llória T. Leishmaniosis canina, una zoonosis grave. 2001;15:1–2. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-leishmaniosis-canina una-zoonosis-grave-13013457
Senasa. Leishmaniasis Visceral Canina Cómo Reconocerla Y Prevenirla Zoonosis. Disponible en: http://www.senasa.gob.ar/sites/default/files/ARBOL_SENASA/SENASA COMUNICA/adjuntos_varios/Zoonosis/leishmaniasis.pdf
Sunter J, Gull K. Shape, form, function and Leishmania pathogenicity: from textbook descriptions to biological understanding. Open Biol [Internet]. el 13 de septiembre de 2017;7(9):170165. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627057/#:~:text=Once inside the macrophage%2C the,now more spherical cell body.
Rios J, Sousa O. Inmunología en la Infección por Leishmania: conceptos actuales. Revista medico cientificada [Internet]. 2011 [citado el 24 de mayo de 2023];1–13. Disponible en: https://www.revistamedicocientifica.org/index.php/rmc/article/view/232/754
Acero P V, Ángel B P, Fonseca B E, Ferrer L, Roura X. Canine Leishmaniosis: tools for diagnosis in veterinary practice in Colombia. Rev MVZ Cordoba [Internet]. el 25 de septiembre de 2015;20(3):4822–42. Disponible en: https://revistamvz.unicordoba.edu.co/article/view/52
Vasquéz L. Terapéutica antileishmania: Revisando el pasado, el presente y el futuro. Gac Med Caracas [Internet]. 2009;117(2):93–111. Disponible en: http://saber.ucv.ve/ojs/index.php/rev_gmc/article/view/18198/144814484606
Martinez M. La Leishmaniasis canina y felina: Revisión bibliográfica del tratamiento actual y de las nuevas terapias de la leishmaniosis canina. 2021;1–20. Disponible en: https://repositori.udl.cat/server/api/core/bitstreams/a35313ac-989c-4c65-a420 b431979d6bd2/content
Santa Maria M, Londoño B, Urquijo L, Gonzalo J, Álvarez V, Benito G. Guia para la atención clínica integral del paciente con leishmaniasis. 2010;1–58. Disponible en: https://www.minsalud.gov.co/Documents/Salud Pública/Ola invernal/Clinica Leishmaniasis.pdf
Camacho I. Leishmaniasis canina: Enfoque actual sobre diagnóstico y prevención [Internet]. 2016 [citado el 12 de septiembre de 2023]. Disponible en: https://www.columbia.edu.py/institucional/revista-cientifica/articulos-de-revision/246 leishmaniasis-canina-enfoque-actual-sobre-diagnostico-y-prevencion
Medrano J. Leishmaniosis. Una zoonosis clásica. 2018;1–4. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-leishmaniosis 13066072
Terrestre M. Leishmaniasis. 2021; Disponible en: https://www.woah.org/fileadmin/Home/esp/Health_standards/tahm/3.01.11_Leishmaniosi s.pdf
Fariñas F. Inmunoterapia e inmunoprofilaxis de la leishmaniosis canina. ¿Que debo saber? [Internet]. 2017. Disponible en: https://www.portalveterinaria.com/animales-de compania/articulos/26859/inmunoterapia-e-inmunoprofilaxis-de-la-leishmaniosis-canina que-debo-saber.html#:~:text=En la leishmaniosis%2C la idea,resistencia en el animal enfermo
Steverding D. The history of leishmaniasis. Parasit Vectors [Internet]. 2017;10:1–10. Disponible en: https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071 017-2028-5
Parada V. Leishmania visceral en Colombia: una revision historica [Internet]. Universidad Cooperativa de Colombia; 2021. Disponible en: https://repository.ucc.edu.co/items/de7dcf75-09bd-4156-a8d0-4d7714494977
Costanzo O. Leishmaniosis visceral: a 101 años del primer caso diagnosticado en las Américas. Memorias del Instituto de Investigaciones en Ciencias de la Salud [Internet]. 2012;10(1):100–4. Disponible en: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1812-95282012000100013
Granado Abadías, Diago A, Cerro A, Palma E, Gilaberte. Leishmaniasis cutánea y mucocutánea. Actas Dermosifiliogr [Internet]. 2021;112(7):601–18. Disponible en: https://www.actasdermo.org/es-leishmaniasis-cutanea-mucocutanea-articulo S0001731021001083
Lizarazo F, Echeverri J, Mendigaña F, Ayala M, Cortés L, Gómez J. Lineamientos de Atención Integral De Leishmaniasis En Colombia. 2023;1–43. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/PAI/Lineamie ntos-leishmaniasis.pdf
Velez R, Gállego M. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Tropical Medicine and International Health [Internet]. 2020;25(5):540–57. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/tmi.13382
Burza S, Croft S, Boelaert M. Leishmaniasis. The Lancet [Internet]. 2018;392(10151):951–70. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31204 2/fulltext#articleInformation
García M. Inmunoparasitología De Leishmania [Internet]. Vol. 1, Facultad De Farmacia Universidad Complutense De Madrid. Facultad De Farmacia Universidad Complutense De Madrid; 2017. Disponible en: http://147.96.70.122/Web/TFG/TFG/Memoria/MACARENA GARCIA-TREVIJANO CABETAS.pdf
Cairó Vilagran J, Font Grau J. Leishmaniosis Canina. Aspectos clínicos. Clínica Veterinaria de Pequeños Animales [Internet]. 1991;11(2):73–81. Disponible en: https://core.ac.uk/download/pdf/33160026.pdf
Romairone A. Leishmaniasis cutánea canina I [Internet]. 2018. Disponible en: https://www.diagnosticoveterinario.com/leishmaniasis-cutanea-un-caso-clinico/2446
Ferrer L, Roura X. Signos clínicos de la leishmaniasis canina [Internet]. 2010. Disponible en: https://www.portalveterinaria.com/animales-de-compania/articulos/21042/signos clinicos-de-la-leishmaniosis-canina.html
Bi K, Chen Y, Zhao S, Kuang Y, Wu C hang J. Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study. Biomed Res Int [Internet]. 2018;1–14. Disponible en: https://www.hindawi.com/journals/bmri/2018/9872095/
Scayola M, Supparo E, Cedano J, Hernández Z. Leishmaniosis visceral: presentación en perros de la ciudad de Salto, Uruguay. Veterinaria (Montevideo) [Internet]. 2019;55(211):1–10. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-48092019000100037
Aguilera C, Wasilchuk M, Cabello A, Aguayo N. Manual de diagnóstico y tratamiento de la leishmaniasis. 2018;1–93. Disponible en: https://www.mspbs.gov.py/dependencias/imt/adjunto/057510 MANUALLEISHMANIASISSENEPA50618actualizado.pdf
Correa F, Romero R. Guia para la atención médica de la leishmaniasis en México. 2022;1–64. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/763280/Guia_Atencion_Leishmanaisis_ Me_xico.pdf
Armúa M, Venzal J. Leishmaniosis: breve puesta al día. Veterinaria (Montevideo) [Internet]. 2019;55(211):1–8. Disponible en: http://www.scielo.edu.uy/pdf/vet/v55n211/1688-4809-vet-55-211-29.pdf
Cáceres A. Rerporte de caso, leishmaniasis en paciente canino (Canis lupus familiaris) de la raza pug en la clínica veterinaria animales de compañia de la universidad cooperativa de Colombia. 2020;1–42. Disponible en: https://repository.ucc.edu.co/server/api/core/bitstreams/f577f17a-78ed-4e0d-a556 3377bb12e7e9/content
Lenis A. La respuesta celular inmune en la leishmaniasis cutánea americana. Biomédica [Internet]. 1998;18(4):274–84. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/998
Agudelo S, Robledo S. Respuesta inmune en infecciones humanas por Leishmania spp. Iatreia [Internet]. 2000;13(3):1–12. Disponible en: https://revistas.udea.edu.co/index.php/iatreia/article/download/3775/3492/0
Huaynates G. Leishmaniasis canina [Internet]. Universidad Nacional Mayot de San Marcos; 2009. Disponible en: https://cybertesis.unmsm.edu.pe/bitstream/handle/20.500.12672/688/Huaynates_og.pdf?se quence=1&isAllowed=y
Rueda K. Prevalencia de anticuerpos frente a Leishmania spp en Canis familiaris de un foco mixto de leishmaniasis en el área urbana del municipio de ovejas, sucre. 2015;1–90. Disponible en: https://repositorio.unisucre.edu.co/bitstream/handle/001/532/T599.74442 R918.pdf?sequence=1&isAllowed=y
Apostolopoulos N, Mitropoulou A, Thom N, Moritz A. Aktuelle Kenntnisse zu Therapie und Prävention der kaninen Leishmaniose. Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere [Internet]. 2018;46(05):315–22. Disponible en: https://www.thieme connect.com/products/ejournals/abstract/10.15654/TPK-180089
Facualtad de veterinaria Universidad Complutense de Madrid. Leishmaniasis canina y felina. Leishvet [Internet]. 2018;14. Disponible en: http://www.leishvet.org/wp content/uploads/2018/09/ES-Guidelines.pdf
Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: New perspectives for old drugs. Molecules [Internet]. 2009;14(7):1–20. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254722/
Nogueira F, Avino V, Galvis F, Pereira V, Batistella M, Peres A, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasit Vectors [Internet]. 2019;12:1–11. Disponible en: https://parasitesandvectors.biomedcentral.com/counter/pdf/10.1186/s13071-019-3323 0.pdf
Woerly V, Maynard L, Sanquer A, Eun HM. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol Res [Internet]. 2009;105:1–7. Disponible en: https://link.springer.com/article/10.1007/s00436-009-1404-2
Ferreira de jesus L. Xanthinuria secondary to allopurinol therapy in dogs with canina leishmaniosis: current perspectives of the iberian veterinary community [Internet]. Universidade de Lisboa Faculdade de Medicina Veterinaria; 2021. Disponible en: https://www.repository.utl.pt/bitstream/10400.5/21665/1/Xanthinuria secondary to allopurinolt therapy in dogs with canine leishmaniosis_current perspectives of the Iberian Veterinary Community.pdf
Llano E, Maidana H, Báez A, Cabrera W, Benítez J. Allopurinol y domperidona en el tratamiento de leishmaniosis visceral canina. Revista Veterinaria [Internet]. 2020;31(1):1 8. Disponible en: https://www.researchgate.net/publication/347738883_Allopurinol_y_domperidona_en_el_ tratamiento_de_leishmaniosis_visceral_canina
Torres M, Pastor J, Roura X, Tabar M, Espada Y, Font A, et al. Adverse urinary effects of allopurinol in dogs with leishmaniasis. Journal of Small Animal Practice [Internet]. 2016;57:1–6. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.12484
González I. Eficacia y tolerabilidad de una nueva formulación de anfotericina b en perros naturalmente infectados por leishmania [Internet]. Universidad CEU Cardenal Herrera; 2017. Disponible en: https://repositorioinstitucional.ceu.es/handle/10637/8724
Baxarias M, Martinez P, Baneth G, Solano L. Immunotherapy in clinical canine leishmaniosis: a comparative update. Res Vet Sci [Internet]. 2019;1–9. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0034528818331886?via%3Dihub
Bruni G, Maietta M, Scotti F, Maggi L, Bini M, Ferrari S, et al. Structure and properties of domperidone and its succinate salt. Acta Crystallogr B Struct Sci Cryst Eng Mater [Internet]. 2013;362–70. Disponible en: http://scripts.iucr.org/cgi bin/paper?S2052519213016989
Sabaté D, Llinás J, Homedes J, Sust M, Ferrer L. A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area. Prev Vet Med [Internet]. 2014;115(1–2):56–63. Disponible en: http://dx.doi.org/10.1016/j.prevetmed.2014.03.010
Cavalera M, Gernone F, Uva A, D’Ippolito P, Roura X, Paltrinieri S, et al. Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease. Parasit Vectors [Internet]. 2021;14:1–9. Disponible en: https://doi.org/10.1186/s13071-021-05030-8
Gomez P, Castillo J, Gascón M, Zarate JJ, Alvarez F, Couto CG. Use of domperidone in the treatment of canine visceral leishmaniasis: A clinical trial. Veterinary Journal [Internet]. 2009;179(2):259–63. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1090023307003358
Segarra S. Nutritional modulation of the immune response mediated by nucleotides in canine leishmaniosis. Microorganisms [Internet]. 2021;9. Disponible en: https://www.mdpi.com/2076-2607/9/12/2601
Fariñas F. Conceptos básicos en inmunonutrición general y quirúrgica [Internet]. 2023 [citado el 15 de octubre de 2023]. Disponible en: https://www.portalveterinaria.com/animales-de-compania/articulos/24946/conceptos basicos-en-inmunonutricion-general-y-quirurgica.html
Santos D, Saraiva J, Vicente A, Moldão-Martins M. Methods for determining bioavailability and bioaccessibility of bioactive compounds and nutrients [Internet]. Innovative Thermal and Non-Thermal Processing, Bioaccessibility and Bioavailability of Nutrients and Bioactive Compounds. Elsevier Inc.; 2019. 23–54 p. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/B9780128141748000020
National Human Genome Research Institute. Nucleótido [Internet]. 2023 [citado el 16 de octubre de 2023]. Disponible en: https://www.genome.gov/es/genetics glossary/Nucleotido
Lane A, Fan T. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res [Internet]. 2015;43:2466–85. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344498/
Lopez E. Alimentación complementaria inmunitario de perros y gatos . 2022; Disponible en: https://www.vanguardiaveterinaria.com.mx/_files/ugd/d5d8b6_5555125c84ac4217889eb2 3f70d5c83c.pdf?index=true
Dea-Ayuela M, Segarra S, Serrano D, Bolás F. Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells. Molecules [Internet]. 2020;25(17). Disponible en: https://www.mdpi.com/1420-3049/25/17/3918
Takanari J, Sato A, Waki H, Miyazaki S, Uebaba K, Hisajima T. Effects of AHCC® on Immune and Stress Responses in Healthy Individuals. J Evid Based Integr Med [Internet]. 2018;23:1–9. Disponible en: https://journals.sagepub.com/doi/full/10.1177/2156587218756511?rfr_dat=cr_pub++0pub med&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Bioiberica. Vademecum Companion Animal Health [Internet]. 2021 [citado el 21 de octubre de 2023]. p. 10. Disponible en: https://www.ganavicola.es/fichastecnicas/VADEMECUM BIOIBERICA.pdf
Segarra S, Miró G, Montoya A, Pardo L, Boqué N, Ferrer L, et al. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. Vet Parasitol [Internet]. 2017;239:50–6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28495197/
Segarra S, Miró G, Montoya A, Pardo L, Teichenné J, Ferrer L, et al. Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound. Parasit Vectors. 2018;11(1):1–10.
Oryan A. Plant-derived compounds in treatment of leishmaniasis. Iran J Vet Res [Internet]. 2015;16:1–19. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789233/
Anand A, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn Rev [Internet]. 2016;10(20):84–9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214562/
Virginia DV, Owen H, Poapolathep A, Mario G. Natural substances as new potential strategies for the treatment of Leishmaniosisin Dogs. Am J Anim Vet Sci [Internet]. 2017;169–75. Disponible en: https://thescipub.com/pdf/ajavsp.2017.169.175.pdf
Tabrez S, Rahman F, Ali R, Akand S, Alaidarous M, Banawas S, et al. Hesperidin Targets Leishmania donovani Sterol C-24 Reductase to Fight against Leishmaniasis. ACS Omega [Internet]. 2021;6:8112–8. Disponible en: https://pubs.acs.org/doi/10.1021/acsomega.0c05858
Lamba S, Roy A. Unveiling the Potential of Hesperidin Targeting the Topoisomerase I Against Leishmania Donovani. 2023;1–39. Disponible en: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4327233
Kumar V, Kt M, Sharma A, Bisht P, Dhingra S, Ravichandiran V, et al. The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis. Biol Trace Elem Res [Internet]. 2022;201(4):1672–88. Disponible en: https://link.springer.com/article/10.1007/s12011-022-03311-6
Sultana S, Ghosh J, Chakraborty S, Mukherjee D, Dey S, Mallick S, et al. Selective in vitro inhibition of Leishmania donovani by a semi-purified fraction of wild mushroom Grifola frondosa. Exp Parasitol [Internet]. 2018;192:73–84. Disponible en: https://doi.org/10.1016/j.exppara.2018.07.006
Das A, Das M, Das N, Bhattacharjee S. Evaluation of the antileishmanial potency, toxicity and phytochemical constituents of methanol bark extract of Sterculia villosa. Pharm Biol [Internet]. 2017;55(1):998–1009. Disponible en: https://www.tandfonline.com/doi/full/10.1080/13880209.2017.1285946
Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int [Internet]. 2013;62(3):253–61. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1383576913000111?via%3Dihub
Tripathi C, Kushawaha P, Sangwan R, Mandal C, Misra-Bhattacharya S, Dube A. Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters. Phytomedicine [Internet]. 2017;24:87–95. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0944711316302161?via%3Dihub
Albalawi A, Alanazi A, Sharifi I, Ezzatkhah F. A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents. Acta Parasitol [Internet]. 2021;66(3):797–811. Disponible en: https://link.springer.com/article/10.1007/s11686-021 00351-1
Chauhan I, Rao S, Shankar J, Chauhan L, Kapadia G, Singh N. Chemoprevention of Leishmaniasis: In-vitro antiparasitic activity of dibenzalacetone, a synthetic curcumin analog leads to apoptotic cell death in Leishmania donovani. Parasitol Int [Internet]. 2018;67(5):627–36. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1383576918300357?via%3Dihub
Bamigbola IE, Ali S. Paradoxical immune response in leishmaniasis: The role of toll-like receptors in disease progression. Parasite Immunol [Internet]. 2022;44(4–5):1–13. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/pim.12910
Hernández J, Salaiza N, Carrada G, Escoto S, Ruiz A, Rosenstein Y, et al. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: The latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis [Internet]. 2010;4(11):1–12. Disponible en: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000871
Regli I, Passelli K, Martínez B, Amore J, Hurrell B, Müller AJ, et al. TLR7 Sensing by Neutrophils Is Critical for the Control of Cutaneous Leishmaniasis. Cell Rep [Internet]. 2020;31(10). Disponible en: https://www.cell.com/cell-reports/fulltext/S2211 1247(20)30726 9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211 124720307269%3Fshowall%3Dtrue
Saha A, Roy S, Ukil A. Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis. Infect Immun [Internet]. 2022;90(8). Disponible en: https://journals.asm.org/doi/10.1128/iai.00248-22?url_ver=Z39.88 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed
Körner H, McMorran B, Schlüter D, Fromm P. The role of TNF in parasitic diseases: Still more questions than answers. Int J Parasitol [Internet]. 2010;40(8):879–88. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0020751910001219?via%3Dihub
Ghosh S, Roy K, Rajalingam R, Martin S, Pal C. Cytokines in the generation and function of regulatory T cell subsets in leishmaniasis. Cytokine [Internet]. 2021;147:155–266. Disponible en: https://doi.org/10.1016/j.cyto.2020.155266
Okwor I, Uzonna J. Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis. Cell Immunol [Internet]. 2016;309:32–6. Disponible en: http://dx.doi.org/10.1016/j.cellimm.2016.06.004
Christodoulides M. Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges [Internet]. Christodoulides M, editor. Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges. Springer; 2023. 287–288 p. Disponible en: https://link.springer.com/book/10.1007/978-3-031-24355-4
Dantas F. Leishmune® vaccine: The newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol [Internet]. 2006;141(1–2):1–8. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0304401706002834?via%3Dihub
Nogueira F, Moreira M, Borja-Cabrera G, Santos F, Menz I, Parra L, et al. Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis: Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine [Internet]. 2005;23(40):4805–10. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0264410X0500530X?via%3Dihub
Velez R, Domenech E, Rodríguez A, Barrios D, Tebar S, Fernández A, et al. Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area–A randomized controlled trial. Acta Trop [Internet]. 2020;205. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0001706X19316729?via%3Dihub
Cacheiro C, Parody N, Renshaw A, Osuna C, Alonso C, Carnés J. Vaccination with LetiFend® reduces circulating immune complexes in dogs experimentally infected with L. infantum. Vaccine [Internet]. 2020;38(4):890–6. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0264410X19314677?via%3Dihub
Baxarias M. Leishmania infantum infection in dogs: from diagnosis to immunotherapy and prevention Tesi doctoral [Internet]. Universitat Autónoma de Barcelona; 2022. Disponible en: https://ddd.uab.cat/pub/tesis/2023/hdl_10803_688401/mbc1de1.pdf
Gonçalves A, Leite J, Resende L, Mariano RM da S, Silveira P, Melo-Júnior OA de O, et al. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy. Front Cell Infect Microbiol [Internet]. 2019;9:1–27. Disponible en: https://www.frontiersin.org/articles/10.3389/fcimb.2019.00427/full
Klingemann H. Immunotherapy for dogs: Running behind humans. Front Immunol [Internet]. 2018;9(FEB):5–10. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2018.00133/full#:~:text=A number of excellent reviews,efficacy in well-designed studies.
Roatt BM, Aguiar-Soares RD de O, Coura-Vital W, Ker HG, Moreira N das D, Vitoriano Souza J, et al. Immunotherapy and immunochemotherapy in visceral leishmaniasis: Promising treatments for this neglected disease. Front Immunol [Internet]. 2014;5(JUN). Disponible en: https://www.frontiersin.org/articles/10.3389/fmed.2023.1096458/full#:~:text=Numerous studies have shown that,improved parasite killing (56%25).
Yasur-Landau D, Jaffe CL, Doron-Faigenboim A, David L, Baneth G. Induction of allopurinol resistance in Leishmania infantum isolated from dogs. PLoS Negl Trop Dis [Internet]. 2017;1–10. Disponible en: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005910
Travi B, Miró G. Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. Mem Inst Oswaldo Cruz [Internet]. 2018;113(11):1–4. Disponible en: https://www.scielo.br/j/mioc/a/mdBvKQNJLT8QrJWsCXZMQ7z/
Hussain K, Abbas RZ, Abbas A, Raza MA, Mahmood MS, Imran M, et al. Therapeutic potential of medicinal plants against leishmaniasis: A public health concern. Bol Latinoam Caribe Plantas Med Aromat [Internet]. 2021;1–9. Disponible en: https://blacpma.ms editions.cl/index.php/blacpma/article/view/137/133
dc.rights.license.none.fl_str_mv Atribución – No comercial – Compartir igual
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Atribución – No comercial – Compartir igual
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.none.fl_str_mv 81 p.
dc.publisher.none.fl_str_mv Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina Veterinaria y Zootecnia, Ibagué
dc.publisher.program.none.fl_str_mv Medicina veterinaria y zootecnia
dc.publisher.place.none.fl_str_mv Ibagué
publisher.none.fl_str_mv Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina Veterinaria y Zootecnia, Ibagué
institution Universidad Cooperativa de Colombia
bitstream.url.fl_str_mv https://repository.ucc.edu.co/bitstreams/9ceed667-62fd-4adf-b1e7-967bed8695db/download
https://repository.ucc.edu.co/bitstreams/e86835bb-8b43-4506-acdc-1103aa7cf3ca/download
https://repository.ucc.edu.co/bitstreams/11e0c736-9548-4668-a7f7-c7b56cef6b62/download
https://repository.ucc.edu.co/bitstreams/65dffafe-753d-4c7b-9333-7401d141a5a1/download
https://repository.ucc.edu.co/bitstreams/d4b091ca-f600-4f58-93c6-f3721bd45965/download
https://repository.ucc.edu.co/bitstreams/c9fa8e08-e376-409d-a831-114dc959293c/download
https://repository.ucc.edu.co/bitstreams/2e67a04b-7a32-408e-8f41-de340ae11b20/download
https://repository.ucc.edu.co/bitstreams/7e674dac-2871-49ce-b578-6b7b05c6657c/download
https://repository.ucc.edu.co/bitstreams/39fb5a2c-642f-4adc-9467-431c9c22f955/download
https://repository.ucc.edu.co/bitstreams/0421fee1-f3f1-4c8b-9588-9e613975ca4b/download
https://repository.ucc.edu.co/bitstreams/fce67a66-00eb-4240-a051-e2b1e9eb5e19/download
https://repository.ucc.edu.co/bitstreams/a654de39-c1cb-4bab-b243-cb28a2906085/download
https://repository.ucc.edu.co/bitstreams/d7b2716f-d5bd-40c1-a68a-273940f3f0a0/download
bitstream.checksum.fl_str_mv 3bce4f7ab09dfc588f126e1e36e98a45
2efa8dc2e59bff310e270571ae5f1be6
a2e2cba1155bfe6d8f36c23fd614e289
6984a4cbab123850702642ff21916148
f38034740a2f0b3101dc4ad59730e3fd
64e14dc08c59c9da2bd78dda9aaca566
9ba62d2407fb124df50066b7adfe76cb
5abd07d77b01da0effbf4983100f579b
d02561358c336b92a9e4d481c1edec24
f0bd8bb5fed60425209153cdc6b67637
20f3a38581a3e7bc3b6742807d8d4e11
afc95ca4e67230123ef7df730c3a4981
f80f2cefca6e2534c857e70c7cdf2142
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Cooperativa de Colombia
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1814246863782543360
spelling Plazas Hernández, Fernely AugustoPérez Rubio, María del Rocío Caro Linares, Daniel AndrésRocha Rodriguez, Luisa Fernanda2023-12-13T15:52:55Z2023-12-13T15:52:55Z2023-12-13https://hdl.handle.net/20.500.12494/53800Caro Linares, D. A. y Rocha Rodriguez, L. F. (2023). Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis canina. [Tesis de pregrado, Universidad Cooperativa de Colombia]. Repositorio Institucional UCC. https://repository.ucc.edu.co/handle/20.500.12494/53800La leishmaniasis es una enfermedad zoonótica causada por el protozoario Leishmania spp, el cual presenta dos estadios en su ciclo de vida (amastigote y promastigote) siendo los amastigotes intracelulares obligados. Este patógeno ataca principalmente células del sistema inmunitario por lo que desencadena diversos procesos tales como los de tipo inflamatorio. Actualmente en caninos se usan diferentes fármacos para su tratamiento pero estos son desgastantes ya que presentan efectos adversos, son costosos y su uso prolongado ha causado resistencia, lo que potencia las lesiones causadas por el parásito, por esta razón se exponen alternativas como coadyuvantes para el tratamiento y control de la enfermedad que actúan sobre el sistema inmunológico de manera directa o indirecta, como por ejemplo la domperidona, los nucleótidos y compuesto correlacionado de hexosa activa (AHCC), extractos de plantas, receptores tipo toll (TLR) y citocinas, además se mencionan las vacunas disponibles comercialmente para su uso como método preventivo.Leishmaniasis is a zoonotic disease caused by the protozoan Leishmania spp, which has two stages in its life cycle (amastigote and promastigote). In the amastigote stage, the parasite is forced to live inside the cell. This pathogen mainly attacks of the cells of the immune system, triggering various processes such as an inflammatory response. Currently, in canines, there are different drugs used for its treatment, but these can worsen the condition due to their adverse side effects. Additionally, they are expensive, and their prolonged use tends to develop resistance, which worsens the damage caused by the parasite. For this reason, this article offers alternatives as adjuvants for the treatment and control of this disease that act on the immune system directly or indirectly. For example, domperidone, nucleotides, Active Hexose Correlated Compound (AHCCs), plant extracts, Toll-like receptors (TLRs), and cytokines. Finally, there are commercially available vaccines for use as a preventive method.1. Introducción. -- 2. Planteamiento del problema. -- 3. Justificación. -- 4. Estado del arte. -- 5. Marco de referencia. -- 5.1 Leishmaniasis. -- 5.2 Presentación clínica. -- 5.2.1 Leishmaniasis cutánea. -- 5.2.2 Leishmaniasis visceral. -- 5.3 Transmisión y ciclo de vida. -- 5.4 Inmunopatología. -- 5.5 Tratamiento. -- 5.5.1 Antimoniales pentavalentes. -- 5.5.2 Miltefosina. -- 5.5.3 Alopurinol. -- 5.5.4 Anfotericina B. -- 5.6 Alternativas inmunomoduladoras como coadyuvantes en el tratamiento contra leishmania spp en caninos. -- 5.6.1 Domperidona. -- 5.6.2 Inmunonutrición y compuestos bioactivos. -- 5.6.3 Terapia herbaria o vegetal. -- 5.6.4 Agonistas del receptor tipo Toll (TLR). -- 5.6.5 Citocinas. -- 5.7 Vacunas como prevención para la Leishmania spp. -- 5.7.1 Leishmune ®. -- 5.7.2 Leish – Tec ®. -- 5.7.3 CaniLeish ®. -- 5.7.4 Letifend ®. -- 6. Objetivos. -- 6.1 Objetivo general. -- 6.2 Objetivos específicos. -- 7. Metodología. -- 8. Resultados. -- 8.1 Presentación de las publicaciones seleccionadas. -- 8.1.1 Artículo 1 “La leishmaniosis canina y felina: Revisión bibliográfica del tratamiento actual y de las nuevas terapias de la leishmaniosis canina”. -- 8.1.2 Artículo 2 “Terapéutica antileishmania: revisando el pasado, presente y el futuro”. -- 8.1.3 Artículo 3 “Leishmania infantum infection in dogs: from diagnosis to immunotherapy and prevention”. -- 8.1.4 Artículo 4 “An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy”. -- 8.1.5 Artículo 5 “Immunotherapy for dogs: Running behind humans”. -- 8.1.6 Artículo 6 “Immunotherapy and immunochemotherapy in visceral leishmaniasis: Promising treatments for this neglected disease”. -- 8.1.7 Artículo 7 “Plant-derived compounds in treatment of leishmaniasis”. -- 8.1.8 Artículo 8 “A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area”. -- 8.1.9 Artículo 9 “Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease”. -- 8.1.10 Artículo 10 “Use of domperidone in the treatment of canine visceral leishmaniasis: A clinical trial”. -- 8.1.11 Artículo 11 “Nutritional Modulation of the Immune Response Mediated by Nucleotides in Canine Leishmaniosis”. -- 8.1.12 Artículo 12 “Immunotherapy in clinical canine leishmaniosis: a comparative update”. -- 8.1.13 Artículo 13 “Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis”. -- 8.1.14 Artículo 14 “Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil”. -- 8.1.15 Artículo 15 “Induction of allopurinol resistance in Leishmania infantum isolated from dogs”. -- 8.1.16 Artículo 16 “ Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications”. -- 8.1.17 Artículo 17 “Allopurinol y domperidona en el tratamiento de leishmaniosis visceral canina”. -- 8.1.19 Artículo 19 “Paradoxical immune response in leishmaniasis: The role of toll-like receptors in disease progression”. -- 8.1.20 Artículo 20 “Natural substances as new potential strategies for the treatment of Leishmaniosis in Dogs”. -- 9. Discusión. -- 10. Conclusiones. -- 11. Referencias.daniel.caro@campusucc.edu.coluisa.rocha@campusucc.edu.co81 p.Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina Veterinaria y Zootecnia, IbaguéMedicina veterinaria y zootecniaIbaguéLutzomya longipalpisSistema inmunológicoCaninosMacrófagosLinfocitosTh1TG 2023 MVZ 53800Lutzomya longipalpisImmune systemCaninesMacrophagesLymphocytesTh1Inmunoterapia como coadyuvante para el tratamiento y control de la leishmaniasis caninaTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/acceptedVersionAtribución – No comercial – Compartir igualinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Llória T. Leishmaniosis canina, una zoonosis grave. 2001;15:1–2. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-leishmaniosis-canina una-zoonosis-grave-13013457Senasa. Leishmaniasis Visceral Canina Cómo Reconocerla Y Prevenirla Zoonosis. Disponible en: http://www.senasa.gob.ar/sites/default/files/ARBOL_SENASA/SENASA COMUNICA/adjuntos_varios/Zoonosis/leishmaniasis.pdfSunter J, Gull K. Shape, form, function and Leishmania pathogenicity: from textbook descriptions to biological understanding. Open Biol [Internet]. el 13 de septiembre de 2017;7(9):170165. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627057/#:~:text=Once inside the macrophage%2C the,now more spherical cell body.Rios J, Sousa O. Inmunología en la Infección por Leishmania: conceptos actuales. Revista medico cientificada [Internet]. 2011 [citado el 24 de mayo de 2023];1–13. Disponible en: https://www.revistamedicocientifica.org/index.php/rmc/article/view/232/754Acero P V, Ángel B P, Fonseca B E, Ferrer L, Roura X. Canine Leishmaniosis: tools for diagnosis in veterinary practice in Colombia. Rev MVZ Cordoba [Internet]. el 25 de septiembre de 2015;20(3):4822–42. Disponible en: https://revistamvz.unicordoba.edu.co/article/view/52Vasquéz L. Terapéutica antileishmania: Revisando el pasado, el presente y el futuro. Gac Med Caracas [Internet]. 2009;117(2):93–111. Disponible en: http://saber.ucv.ve/ojs/index.php/rev_gmc/article/view/18198/144814484606Martinez M. La Leishmaniasis canina y felina: Revisión bibliográfica del tratamiento actual y de las nuevas terapias de la leishmaniosis canina. 2021;1–20. Disponible en: https://repositori.udl.cat/server/api/core/bitstreams/a35313ac-989c-4c65-a420 b431979d6bd2/contentSanta Maria M, Londoño B, Urquijo L, Gonzalo J, Álvarez V, Benito G. Guia para la atención clínica integral del paciente con leishmaniasis. 2010;1–58. Disponible en: https://www.minsalud.gov.co/Documents/Salud Pública/Ola invernal/Clinica Leishmaniasis.pdfCamacho I. Leishmaniasis canina: Enfoque actual sobre diagnóstico y prevención [Internet]. 2016 [citado el 12 de septiembre de 2023]. Disponible en: https://www.columbia.edu.py/institucional/revista-cientifica/articulos-de-revision/246 leishmaniasis-canina-enfoque-actual-sobre-diagnostico-y-prevencionMedrano J. Leishmaniosis. Una zoonosis clásica. 2018;1–4. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-leishmaniosis 13066072Terrestre M. Leishmaniasis. 2021; Disponible en: https://www.woah.org/fileadmin/Home/esp/Health_standards/tahm/3.01.11_Leishmaniosi s.pdfFariñas F. Inmunoterapia e inmunoprofilaxis de la leishmaniosis canina. ¿Que debo saber? [Internet]. 2017. Disponible en: https://www.portalveterinaria.com/animales-de compania/articulos/26859/inmunoterapia-e-inmunoprofilaxis-de-la-leishmaniosis-canina que-debo-saber.html#:~:text=En la leishmaniosis%2C la idea,resistencia en el animal enfermoSteverding D. The history of leishmaniasis. Parasit Vectors [Internet]. 2017;10:1–10. Disponible en: https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071 017-2028-5Parada V. Leishmania visceral en Colombia: una revision historica [Internet]. Universidad Cooperativa de Colombia; 2021. Disponible en: https://repository.ucc.edu.co/items/de7dcf75-09bd-4156-a8d0-4d7714494977Costanzo O. Leishmaniosis visceral: a 101 años del primer caso diagnosticado en las Américas. Memorias del Instituto de Investigaciones en Ciencias de la Salud [Internet]. 2012;10(1):100–4. Disponible en: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1812-95282012000100013Granado Abadías, Diago A, Cerro A, Palma E, Gilaberte. Leishmaniasis cutánea y mucocutánea. Actas Dermosifiliogr [Internet]. 2021;112(7):601–18. Disponible en: https://www.actasdermo.org/es-leishmaniasis-cutanea-mucocutanea-articulo S0001731021001083Lizarazo F, Echeverri J, Mendigaña F, Ayala M, Cortés L, Gómez J. Lineamientos de Atención Integral De Leishmaniasis En Colombia. 2023;1–43. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/PAI/Lineamie ntos-leishmaniasis.pdfVelez R, Gállego M. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Tropical Medicine and International Health [Internet]. 2020;25(5):540–57. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/tmi.13382Burza S, Croft S, Boelaert M. Leishmaniasis. The Lancet [Internet]. 2018;392(10151):951–70. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31204 2/fulltext#articleInformationGarcía M. Inmunoparasitología De Leishmania [Internet]. Vol. 1, Facultad De Farmacia Universidad Complutense De Madrid. Facultad De Farmacia Universidad Complutense De Madrid; 2017. Disponible en: http://147.96.70.122/Web/TFG/TFG/Memoria/MACARENA GARCIA-TREVIJANO CABETAS.pdfCairó Vilagran J, Font Grau J. Leishmaniosis Canina. Aspectos clínicos. Clínica Veterinaria de Pequeños Animales [Internet]. 1991;11(2):73–81. Disponible en: https://core.ac.uk/download/pdf/33160026.pdfRomairone A. Leishmaniasis cutánea canina I [Internet]. 2018. Disponible en: https://www.diagnosticoveterinario.com/leishmaniasis-cutanea-un-caso-clinico/2446Ferrer L, Roura X. Signos clínicos de la leishmaniasis canina [Internet]. 2010. Disponible en: https://www.portalveterinaria.com/animales-de-compania/articulos/21042/signos clinicos-de-la-leishmaniosis-canina.htmlBi K, Chen Y, Zhao S, Kuang Y, Wu C hang J. Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study. Biomed Res Int [Internet]. 2018;1–14. Disponible en: https://www.hindawi.com/journals/bmri/2018/9872095/Scayola M, Supparo E, Cedano J, Hernández Z. Leishmaniosis visceral: presentación en perros de la ciudad de Salto, Uruguay. Veterinaria (Montevideo) [Internet]. 2019;55(211):1–10. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-48092019000100037Aguilera C, Wasilchuk M, Cabello A, Aguayo N. Manual de diagnóstico y tratamiento de la leishmaniasis. 2018;1–93. Disponible en: https://www.mspbs.gov.py/dependencias/imt/adjunto/057510 MANUALLEISHMANIASISSENEPA50618actualizado.pdfCorrea F, Romero R. Guia para la atención médica de la leishmaniasis en México. 2022;1–64. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/763280/Guia_Atencion_Leishmanaisis_ Me_xico.pdfArmúa M, Venzal J. Leishmaniosis: breve puesta al día. Veterinaria (Montevideo) [Internet]. 2019;55(211):1–8. Disponible en: http://www.scielo.edu.uy/pdf/vet/v55n211/1688-4809-vet-55-211-29.pdfCáceres A. Rerporte de caso, leishmaniasis en paciente canino (Canis lupus familiaris) de la raza pug en la clínica veterinaria animales de compañia de la universidad cooperativa de Colombia. 2020;1–42. Disponible en: https://repository.ucc.edu.co/server/api/core/bitstreams/f577f17a-78ed-4e0d-a556 3377bb12e7e9/contentLenis A. La respuesta celular inmune en la leishmaniasis cutánea americana. Biomédica [Internet]. 1998;18(4):274–84. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/998Agudelo S, Robledo S. Respuesta inmune en infecciones humanas por Leishmania spp. Iatreia [Internet]. 2000;13(3):1–12. Disponible en: https://revistas.udea.edu.co/index.php/iatreia/article/download/3775/3492/0Huaynates G. Leishmaniasis canina [Internet]. Universidad Nacional Mayot de San Marcos; 2009. Disponible en: https://cybertesis.unmsm.edu.pe/bitstream/handle/20.500.12672/688/Huaynates_og.pdf?se quence=1&isAllowed=yRueda K. Prevalencia de anticuerpos frente a Leishmania spp en Canis familiaris de un foco mixto de leishmaniasis en el área urbana del municipio de ovejas, sucre. 2015;1–90. Disponible en: https://repositorio.unisucre.edu.co/bitstream/handle/001/532/T599.74442 R918.pdf?sequence=1&isAllowed=yApostolopoulos N, Mitropoulou A, Thom N, Moritz A. Aktuelle Kenntnisse zu Therapie und Prävention der kaninen Leishmaniose. Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere [Internet]. 2018;46(05):315–22. Disponible en: https://www.thieme connect.com/products/ejournals/abstract/10.15654/TPK-180089Facualtad de veterinaria Universidad Complutense de Madrid. Leishmaniasis canina y felina. Leishvet [Internet]. 2018;14. Disponible en: http://www.leishvet.org/wp content/uploads/2018/09/ES-Guidelines.pdfFrézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: New perspectives for old drugs. Molecules [Internet]. 2009;14(7):1–20. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254722/Nogueira F, Avino V, Galvis F, Pereira V, Batistella M, Peres A, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasit Vectors [Internet]. 2019;12:1–11. Disponible en: https://parasitesandvectors.biomedcentral.com/counter/pdf/10.1186/s13071-019-3323 0.pdfWoerly V, Maynard L, Sanquer A, Eun HM. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol Res [Internet]. 2009;105:1–7. Disponible en: https://link.springer.com/article/10.1007/s00436-009-1404-2Ferreira de jesus L. Xanthinuria secondary to allopurinol therapy in dogs with canina leishmaniosis: current perspectives of the iberian veterinary community [Internet]. Universidade de Lisboa Faculdade de Medicina Veterinaria; 2021. Disponible en: https://www.repository.utl.pt/bitstream/10400.5/21665/1/Xanthinuria secondary to allopurinolt therapy in dogs with canine leishmaniosis_current perspectives of the Iberian Veterinary Community.pdfLlano E, Maidana H, Báez A, Cabrera W, Benítez J. Allopurinol y domperidona en el tratamiento de leishmaniosis visceral canina. Revista Veterinaria [Internet]. 2020;31(1):1 8. Disponible en: https://www.researchgate.net/publication/347738883_Allopurinol_y_domperidona_en_el_ tratamiento_de_leishmaniosis_visceral_caninaTorres M, Pastor J, Roura X, Tabar M, Espada Y, Font A, et al. Adverse urinary effects of allopurinol in dogs with leishmaniasis. Journal of Small Animal Practice [Internet]. 2016;57:1–6. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.12484González I. Eficacia y tolerabilidad de una nueva formulación de anfotericina b en perros naturalmente infectados por leishmania [Internet]. Universidad CEU Cardenal Herrera; 2017. Disponible en: https://repositorioinstitucional.ceu.es/handle/10637/8724Baxarias M, Martinez P, Baneth G, Solano L. Immunotherapy in clinical canine leishmaniosis: a comparative update. Res Vet Sci [Internet]. 2019;1–9. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0034528818331886?via%3DihubBruni G, Maietta M, Scotti F, Maggi L, Bini M, Ferrari S, et al. Structure and properties of domperidone and its succinate salt. Acta Crystallogr B Struct Sci Cryst Eng Mater [Internet]. 2013;362–70. Disponible en: http://scripts.iucr.org/cgi bin/paper?S2052519213016989Sabaté D, Llinás J, Homedes J, Sust M, Ferrer L. A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area. Prev Vet Med [Internet]. 2014;115(1–2):56–63. Disponible en: http://dx.doi.org/10.1016/j.prevetmed.2014.03.010Cavalera M, Gernone F, Uva A, D’Ippolito P, Roura X, Paltrinieri S, et al. Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease. Parasit Vectors [Internet]. 2021;14:1–9. Disponible en: https://doi.org/10.1186/s13071-021-05030-8Gomez P, Castillo J, Gascón M, Zarate JJ, Alvarez F, Couto CG. Use of domperidone in the treatment of canine visceral leishmaniasis: A clinical trial. Veterinary Journal [Internet]. 2009;179(2):259–63. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1090023307003358Segarra S. Nutritional modulation of the immune response mediated by nucleotides in canine leishmaniosis. Microorganisms [Internet]. 2021;9. Disponible en: https://www.mdpi.com/2076-2607/9/12/2601Fariñas F. Conceptos básicos en inmunonutrición general y quirúrgica [Internet]. 2023 [citado el 15 de octubre de 2023]. Disponible en: https://www.portalveterinaria.com/animales-de-compania/articulos/24946/conceptos basicos-en-inmunonutricion-general-y-quirurgica.htmlSantos D, Saraiva J, Vicente A, Moldão-Martins M. Methods for determining bioavailability and bioaccessibility of bioactive compounds and nutrients [Internet]. Innovative Thermal and Non-Thermal Processing, Bioaccessibility and Bioavailability of Nutrients and Bioactive Compounds. Elsevier Inc.; 2019. 23–54 p. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/B9780128141748000020National Human Genome Research Institute. Nucleótido [Internet]. 2023 [citado el 16 de octubre de 2023]. Disponible en: https://www.genome.gov/es/genetics glossary/NucleotidoLane A, Fan T. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res [Internet]. 2015;43:2466–85. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344498/Lopez E. Alimentación complementaria inmunitario de perros y gatos . 2022; Disponible en: https://www.vanguardiaveterinaria.com.mx/_files/ugd/d5d8b6_5555125c84ac4217889eb2 3f70d5c83c.pdf?index=trueDea-Ayuela M, Segarra S, Serrano D, Bolás F. Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells. Molecules [Internet]. 2020;25(17). Disponible en: https://www.mdpi.com/1420-3049/25/17/3918Takanari J, Sato A, Waki H, Miyazaki S, Uebaba K, Hisajima T. Effects of AHCC® on Immune and Stress Responses in Healthy Individuals. J Evid Based Integr Med [Internet]. 2018;23:1–9. Disponible en: https://journals.sagepub.com/doi/full/10.1177/2156587218756511?rfr_dat=cr_pub++0pub med&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.orgBioiberica. Vademecum Companion Animal Health [Internet]. 2021 [citado el 21 de octubre de 2023]. p. 10. Disponible en: https://www.ganavicola.es/fichastecnicas/VADEMECUM BIOIBERICA.pdfSegarra S, Miró G, Montoya A, Pardo L, Boqué N, Ferrer L, et al. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. Vet Parasitol [Internet]. 2017;239:50–6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28495197/Segarra S, Miró G, Montoya A, Pardo L, Teichenné J, Ferrer L, et al. Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound. Parasit Vectors. 2018;11(1):1–10.Oryan A. Plant-derived compounds in treatment of leishmaniasis. Iran J Vet Res [Internet]. 2015;16:1–19. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789233/Anand A, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn Rev [Internet]. 2016;10(20):84–9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214562/Virginia DV, Owen H, Poapolathep A, Mario G. Natural substances as new potential strategies for the treatment of Leishmaniosisin Dogs. Am J Anim Vet Sci [Internet]. 2017;169–75. Disponible en: https://thescipub.com/pdf/ajavsp.2017.169.175.pdfTabrez S, Rahman F, Ali R, Akand S, Alaidarous M, Banawas S, et al. Hesperidin Targets Leishmania donovani Sterol C-24 Reductase to Fight against Leishmaniasis. ACS Omega [Internet]. 2021;6:8112–8. Disponible en: https://pubs.acs.org/doi/10.1021/acsomega.0c05858Lamba S, Roy A. Unveiling the Potential of Hesperidin Targeting the Topoisomerase I Against Leishmania Donovani. 2023;1–39. Disponible en: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4327233Kumar V, Kt M, Sharma A, Bisht P, Dhingra S, Ravichandiran V, et al. The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis. Biol Trace Elem Res [Internet]. 2022;201(4):1672–88. Disponible en: https://link.springer.com/article/10.1007/s12011-022-03311-6Sultana S, Ghosh J, Chakraborty S, Mukherjee D, Dey S, Mallick S, et al. Selective in vitro inhibition of Leishmania donovani by a semi-purified fraction of wild mushroom Grifola frondosa. Exp Parasitol [Internet]. 2018;192:73–84. Disponible en: https://doi.org/10.1016/j.exppara.2018.07.006Das A, Das M, Das N, Bhattacharjee S. Evaluation of the antileishmanial potency, toxicity and phytochemical constituents of methanol bark extract of Sterculia villosa. Pharm Biol [Internet]. 2017;55(1):998–1009. Disponible en: https://www.tandfonline.com/doi/full/10.1080/13880209.2017.1285946Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int [Internet]. 2013;62(3):253–61. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1383576913000111?via%3DihubTripathi C, Kushawaha P, Sangwan R, Mandal C, Misra-Bhattacharya S, Dube A. Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters. Phytomedicine [Internet]. 2017;24:87–95. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0944711316302161?via%3DihubAlbalawi A, Alanazi A, Sharifi I, Ezzatkhah F. A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents. Acta Parasitol [Internet]. 2021;66(3):797–811. Disponible en: https://link.springer.com/article/10.1007/s11686-021 00351-1Chauhan I, Rao S, Shankar J, Chauhan L, Kapadia G, Singh N. Chemoprevention of Leishmaniasis: In-vitro antiparasitic activity of dibenzalacetone, a synthetic curcumin analog leads to apoptotic cell death in Leishmania donovani. Parasitol Int [Internet]. 2018;67(5):627–36. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1383576918300357?via%3DihubBamigbola IE, Ali S. Paradoxical immune response in leishmaniasis: The role of toll-like receptors in disease progression. Parasite Immunol [Internet]. 2022;44(4–5):1–13. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/pim.12910Hernández J, Salaiza N, Carrada G, Escoto S, Ruiz A, Rosenstein Y, et al. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: The latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis [Internet]. 2010;4(11):1–12. Disponible en: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000871Regli I, Passelli K, Martínez B, Amore J, Hurrell B, Müller AJ, et al. TLR7 Sensing by Neutrophils Is Critical for the Control of Cutaneous Leishmaniasis. Cell Rep [Internet]. 2020;31(10). Disponible en: https://www.cell.com/cell-reports/fulltext/S2211 1247(20)30726 9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211 124720307269%3Fshowall%3DtrueSaha A, Roy S, Ukil A. Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis. Infect Immun [Internet]. 2022;90(8). Disponible en: https://journals.asm.org/doi/10.1128/iai.00248-22?url_ver=Z39.88 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmedKörner H, McMorran B, Schlüter D, Fromm P. The role of TNF in parasitic diseases: Still more questions than answers. Int J Parasitol [Internet]. 2010;40(8):879–88. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0020751910001219?via%3DihubGhosh S, Roy K, Rajalingam R, Martin S, Pal C. Cytokines in the generation and function of regulatory T cell subsets in leishmaniasis. Cytokine [Internet]. 2021;147:155–266. Disponible en: https://doi.org/10.1016/j.cyto.2020.155266Okwor I, Uzonna J. Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis. Cell Immunol [Internet]. 2016;309:32–6. Disponible en: http://dx.doi.org/10.1016/j.cellimm.2016.06.004Christodoulides M. Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges [Internet]. Christodoulides M, editor. Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges. Springer; 2023. 287–288 p. Disponible en: https://link.springer.com/book/10.1007/978-3-031-24355-4Dantas F. Leishmune® vaccine: The newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol [Internet]. 2006;141(1–2):1–8. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0304401706002834?via%3DihubNogueira F, Moreira M, Borja-Cabrera G, Santos F, Menz I, Parra L, et al. Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis: Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine [Internet]. 2005;23(40):4805–10. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0264410X0500530X?via%3DihubVelez R, Domenech E, Rodríguez A, Barrios D, Tebar S, Fernández A, et al. Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area–A randomized controlled trial. Acta Trop [Internet]. 2020;205. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0001706X19316729?via%3DihubCacheiro C, Parody N, Renshaw A, Osuna C, Alonso C, Carnés J. Vaccination with LetiFend® reduces circulating immune complexes in dogs experimentally infected with L. infantum. Vaccine [Internet]. 2020;38(4):890–6. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0264410X19314677?via%3DihubBaxarias M. Leishmania infantum infection in dogs: from diagnosis to immunotherapy and prevention Tesi doctoral [Internet]. Universitat Autónoma de Barcelona; 2022. Disponible en: https://ddd.uab.cat/pub/tesis/2023/hdl_10803_688401/mbc1de1.pdfGonçalves A, Leite J, Resende L, Mariano RM da S, Silveira P, Melo-Júnior OA de O, et al. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy. Front Cell Infect Microbiol [Internet]. 2019;9:1–27. Disponible en: https://www.frontiersin.org/articles/10.3389/fcimb.2019.00427/fullKlingemann H. Immunotherapy for dogs: Running behind humans. Front Immunol [Internet]. 2018;9(FEB):5–10. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2018.00133/full#:~:text=A number of excellent reviews,efficacy in well-designed studies.Roatt BM, Aguiar-Soares RD de O, Coura-Vital W, Ker HG, Moreira N das D, Vitoriano Souza J, et al. Immunotherapy and immunochemotherapy in visceral leishmaniasis: Promising treatments for this neglected disease. Front Immunol [Internet]. 2014;5(JUN). Disponible en: https://www.frontiersin.org/articles/10.3389/fmed.2023.1096458/full#:~:text=Numerous studies have shown that,improved parasite killing (56%25).Yasur-Landau D, Jaffe CL, Doron-Faigenboim A, David L, Baneth G. Induction of allopurinol resistance in Leishmania infantum isolated from dogs. PLoS Negl Trop Dis [Internet]. 2017;1–10. Disponible en: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005910Travi B, Miró G. Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. Mem Inst Oswaldo Cruz [Internet]. 2018;113(11):1–4. Disponible en: https://www.scielo.br/j/mioc/a/mdBvKQNJLT8QrJWsCXZMQ7z/Hussain K, Abbas RZ, Abbas A, Raza MA, Mahmood MS, Imran M, et al. Therapeutic potential of medicinal plants against leishmaniasis: A public health concern. Bol Latinoam Caribe Plantas Med Aromat [Internet]. 2021;1–9. Disponible en: https://blacpma.ms editions.cl/index.php/blacpma/article/view/137/133PublicationLICENSElicense.txtlicense.txttext/plain; charset=utf-84334https://repository.ucc.edu.co/bitstreams/9ceed667-62fd-4adf-b1e7-967bed8695db/download3bce4f7ab09dfc588f126e1e36e98a45MD51ORIGINAL2023_inmunoterapia_coadyuvante_tratamiento.pdf2023_inmunoterapia_coadyuvante_tratamiento.pdfTrabajo de gradosapplication/pdf732810https://repository.ucc.edu.co/bitstreams/e86835bb-8b43-4506-acdc-1103aa7cf3ca/download2efa8dc2e59bff310e270571ae5f1be6MD522023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion1.pdf2023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion1.pdfActa de susytentación 1application/pdf118876https://repository.ucc.edu.co/bitstreams/11e0c736-9548-4668-a7f7-c7b56cef6b62/downloada2e2cba1155bfe6d8f36c23fd614e289MD532023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion2.pdf2023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion2.pdfActa de sustentación 2application/pdf111725https://repository.ucc.edu.co/bitstreams/65dffafe-753d-4c7b-9333-7401d141a5a1/download6984a4cbab123850702642ff21916148MD542023_inmunoterapia_coadyuvante_tratamiento-FormatoLicenciaUso.pdf2023_inmunoterapia_coadyuvante_tratamiento-FormatoLicenciaUso.pdfLicencia de usoapplication/pdf199584https://repository.ucc.edu.co/bitstreams/d4b091ca-f600-4f58-93c6-f3721bd45965/downloadf38034740a2f0b3101dc4ad59730e3fdMD55TEXT2023_inmunoterapia_coadyuvante_tratamiento.pdf.txt2023_inmunoterapia_coadyuvante_tratamiento.pdf.txtExtracted texttext/plain101906https://repository.ucc.edu.co/bitstreams/c9fa8e08-e376-409d-a831-114dc959293c/download64e14dc08c59c9da2bd78dda9aaca566MD562023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion1.pdf.txt2023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion1.pdf.txtExtracted texttext/plain1372https://repository.ucc.edu.co/bitstreams/2e67a04b-7a32-408e-8f41-de340ae11b20/download9ba62d2407fb124df50066b7adfe76cbMD582023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion2.pdf.txt2023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion2.pdf.txtExtracted texttext/plain1373https://repository.ucc.edu.co/bitstreams/7e674dac-2871-49ce-b578-6b7b05c6657c/download5abd07d77b01da0effbf4983100f579bMD5102023_inmunoterapia_coadyuvante_tratamiento-FormatoLicenciaUso.pdf.txt2023_inmunoterapia_coadyuvante_tratamiento-FormatoLicenciaUso.pdf.txtExtracted texttext/plain5893https://repository.ucc.edu.co/bitstreams/39fb5a2c-642f-4adc-9467-431c9c22f955/downloadd02561358c336b92a9e4d481c1edec24MD512THUMBNAIL2023_inmunoterapia_coadyuvante_tratamiento.pdf.jpg2023_inmunoterapia_coadyuvante_tratamiento.pdf.jpgGenerated Thumbnailimage/jpeg6493https://repository.ucc.edu.co/bitstreams/0421fee1-f3f1-4c8b-9588-9e613975ca4b/downloadf0bd8bb5fed60425209153cdc6b67637MD572023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion1.pdf.jpg2023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion1.pdf.jpgGenerated Thumbnailimage/jpeg10965https://repository.ucc.edu.co/bitstreams/fce67a66-00eb-4240-a051-e2b1e9eb5e19/download20f3a38581a3e7bc3b6742807d8d4e11MD592023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion2.pdf.jpg2023_inmunoterapia_coadyuvante_tratamiento-ActaSustentacion2.pdf.jpgGenerated Thumbnailimage/jpeg11653https://repository.ucc.edu.co/bitstreams/a654de39-c1cb-4bab-b243-cb28a2906085/downloadafc95ca4e67230123ef7df730c3a4981MD5112023_inmunoterapia_coadyuvante_tratamiento-FormatoLicenciaUso.pdf.jpg2023_inmunoterapia_coadyuvante_tratamiento-FormatoLicenciaUso.pdf.jpgGenerated Thumbnailimage/jpeg12587https://repository.ucc.edu.co/bitstreams/d7b2716f-d5bd-40c1-a68a-273940f3f0a0/downloadf80f2cefca6e2534c857e70c7cdf2142MD51320.500.12494/53800oai:repository.ucc.edu.co:20.500.12494/538002024-08-09 12:36:50.32open.accesshttps://repository.ucc.edu.coRepositorio Institucional Universidad Cooperativa de Colombiabdigital@metabiblioteca.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

Publicaciones similares